MedTrace Logo

Fingolimod in Schizophrenia Patients

NCT01779700 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-04-16

Study results available
· View outcomes & findings →

Summary

This will be a single site safety and proof of concept study conducted at the Indiana University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective disorders will be randomized 1:1 to double-blind treatment with fingolimod or matched placebo for duration of 8 weeks.

Conditions

Interventions

DRUG

Fingolimod

0.5mg each day of 8 week cycle

DRUG

placebo

1 tablet each day of 8 week cycle

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Alan Breier, MD · Indiana University

  • Michael Francis, MD · Indiana University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01779700 on ClinicalTrials.gov